Compare PLBY & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLBY | PROF |
|---|---|---|
| Founded | 1953 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.4M | 243.2M |
| IPO Year | 2020 | 2017 |
| Metric | PLBY | PROF |
|---|---|---|
| Price | $1.30 | $6.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.1M | 63.5K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $120,928,000.00 | $16,098,000.00 |
| Revenue This Year | $9.17 | $92.40 |
| Revenue Next Year | $7.10 | $64.10 |
| P/E Ratio | ★ N/A | $35.74 |
| Revenue Growth | 4.13 | ★ 50.73 |
| 52 Week Low | $1.19 | $3.92 |
| 52 Week High | $2.75 | $8.95 |
| Indicator | PLBY | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 46.15 |
| Support Level | $1.22 | $6.54 |
| Resistance Level | $1.94 | $7.07 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 33.90 | 35.67 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.